News
Wellbeing of Women launches partnership to advance women’s health
Wellbeing of Women and Maroon Venture Fund have announced a multi-year partnership to advance women’s health.
The AstraWell partnership is hoped to speed up innovation, venture development and product solutions in women’s health, accelerate deployment of catalytic capital to fund women’s health innovation and increase and strengthen AstraWell’s R&D innovation consortiums, commercial venture platforms, collaborations, and scaling opportunities in women’s health in the UK and abroad.
In the UK, despite living for longer, women spend more time living in poor health than men.
Research into diagnosis, treatment and preventative care is underfunded, with only 2.4 per cent of public research funding going to women’s gynaecological health and childbirth.
Janet Lindsay, chief executive of Wellbeing of Women, said: “We are delighted to announce this partnership with Maroon Venture Fund.
“By supporting exciting new ventures in women’s health, we can nurture great ideas and tackle some of the most pressing issues facing women today, from heavy menstrual bleeding to premature birth, gynaecological cancers and beyond.
“This is the first time we are offering our unrivalled expertise in women’s health to companies working to innovate in this space, and we hope that doing so will help drive forward initiatives to help all women.”
Lisa Lambie, managing partner of Maroon Venture Fund, added: “Through this exciting partnership with Wellbeing of Women, Maroon looks forward to materially advancing critical research and innovation in women’s health; execute this robust scaling catalyst to accelerate commercial launches to market in the US and UK; and tackle some of the most pressing issues in comprehensive women’s health today.
“The most effective health advances do not occur in silos, but are fostered from collaboration across geographies and by ‘best-in-class’ partnerships reflecting deep expertise.
“Maroon is focused on advancing innovation addressing key chronic conditions for population health. These areas also represent health conditions that disproportionately impact women.”
The first initiative under AstraWell is the launch of AstraWell Venture Studio to support the venture development and commercial scaling of early-stage ventures, addressing chronic health and climate conditions disproportionately impacting women’s health.
AstraWell Venture Studio will be a hybrid platform, primarily virtual, also offering optional on-site engagement and sessions in New York, Boston, Houston, Glasgow and London.
Ventures interested in applying to AstraWell Venture Studio are invited to complete the applicant questionnaire and also attend the Information Session on Wednesday 3 July by RSVP HERE.
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







1 Comment